<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03808311</url>
  </required_header>
  <id_info>
    <org_study_id>Ruijin-2018-138-2</org_study_id>
    <nct_id>NCT03808311</nct_id>
  </id_info>
  <brief_title>Blood Pressure Control Target in Diabetes</brief_title>
  <acronym>BPROAD</acronym>
  <official_title>Blood Pressure Control Target in Diabetes (BPROAD): A Multicenter, Open-label, Parallel-group, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, parallel-group, randomized controlled trial that will be&#xD;
      conducted across mainland China. This trial will test the primary hypothesis of whether an&#xD;
      intensive treatment strategy (a systolic blood pressure target of &lt;120 mmHg) is more&#xD;
      effective than a standard treatment strategy (a systolic blood pressure target of &lt;140 mmHg)&#xD;
      in reducing the risk of major cardiovascular disease (non-fatal stroke, non-fatal myocardial&#xD;
      infarction, treated or hospitalized heart failure, and cardiovascular deaths) over a&#xD;
      follow-up period of up to 5 years among patients with a history of diabetes and elevated&#xD;
      systolic blood pressure. The secondary hypotheses are to compare the intensive blood pressure&#xD;
      treatment strategy with the standard treatment strategy on dementia and cognitive function,&#xD;
      individual components of the primary hypothesis, all-cause mortality, kidney outcomes,&#xD;
      quality of life, and injurious falls, et al.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will recruit 12,702 patients from approximately 200 hospitals within the China&#xD;
      Diabetes Clinical Research Network. Eligible criteria include men and women aged ≥50 years;&#xD;
      type 2 diabetes mellitus; elevated systolic blood pressure; and a history of clinical&#xD;
      cardiovascular disease or increased risk for cardiovascular disease. Main exclusion criteria&#xD;
      include known secondary cause of hypertension, symptomatic heart failure, end-stage renal&#xD;
      disease, and other serious illness. The proposed trial has 90% statistical power to detect a&#xD;
      20% reduction (hazard ratio of 0.80) in major cardiovascular disease between intensive and&#xD;
      standard treatment groups at a 2-sided significance level of 0.05.&#xD;
&#xD;
      To achieve the proposed study objectives, the following specific aims will be accomplished:&#xD;
&#xD;
        1. Recruit 12,702 study participants who meet the eligibility criteria and randomly assign&#xD;
           6,351 to the intensive blood pressure treatment and 6,351 to the standard blood pressure&#xD;
           treatment groups;&#xD;
&#xD;
        2. Achieve and maintain two-level targets of systolic blood pressure (&lt;120 mmHg vs. &lt;140&#xD;
           mmHg) with a mean systolic blood pressure difference of ≥15 mmHg;&#xD;
&#xD;
        3. Employ a study-wide strategy to encourage standard of care for all participants for the&#xD;
           treatment of type 2 diabetes and dyslipidemia other than blood pressure;&#xD;
&#xD;
        4. Obtain clinical data on study outcomes for up to 60 months of follow-up among all trial&#xD;
           participants;&#xD;
&#xD;
        5. Perform strict quality control procedures for intervention and data collection;&#xD;
&#xD;
        6. Conduct data analysis according to the intention-to-treat principle; and&#xD;
&#xD;
        7. Disseminate the study findings to influence clinical practice and clinical guidelines.&#xD;
&#xD;
      Findings from this trial will provide evidence as to whether intensive blood pressure&#xD;
      management to achieve a systolic blood pressure target of &lt;120 mmHg has additional benefits&#xD;
      over standard management of systolic blood pressure &lt;140 mmHg. These findings will help in&#xD;
      the development of clinical guidelines for blood pressure management among patients with type&#xD;
      2 diabetes and will have important clinical impact.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>5 years</time_frame>
    <description>Time to the first occurrence of any of the following: non-fatal stroke, non-fatal myocardial infarction, hospitalized or treated heart failure, or cardiovascular deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A composite of the primary outcome and all-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Time to the first occurrence of any of the following: non-fatal stroke, non-fatal MI, hospitalized or treated heart failure, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular outcome</measure>
    <time_frame>5 years</time_frame>
    <description>Time to the first occurrence of any of the following: non-fatal stroke, non-fatal MI, hospitalized or treated heart failure, cardiovascular deaths, treated or hospitalized unstable angina, or any cardiovascular revascularization procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major coronary artery diseases</measure>
    <time_frame>5 years</time_frame>
    <description>Time to the first occurrence of any of the following: non-fatal MI, treated or hospitalized unstable angina, revascularization of coronary arteries, or deaths due to coronary artery diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Fatal and non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
    <time_frame>5 years</time_frame>
    <description>Hospitalized or treated heart failure, or heart failure death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>5 years</time_frame>
    <description>Deaths due to cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Deaths due to any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of all-cause dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluated with HQoL scales such as Short Form 12 Health Survey Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Progression of CKD, development of CKD, and incident albuminuria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>All cardiovascular revascularization procedures</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treated or hospitalized unstable angina</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Retinopathy</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transient ischemic attack (TIA)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular hypertrophy (LVH)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Atrial fibrillation or flutter</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All cancers</measure>
    <time_frame>5 years</time_frame>
    <description>Time to the first occurrence of any types of cancer</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>5 years</time_frame>
    <description>The incremental cost per quality adjusted life year (QALY) gained. QALYs will be measured by the EuroQol-5 Dimensions (EQ-5D) questionnaire.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12702</enrollment>
  <condition>Blood Pressure Control Target in Diabetes</condition>
  <arm_group>
    <arm_group_label>Intensive BP treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intensive BP treatment arm will be treated to a systolic BP target of &lt;120 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard BP treatment arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in the standard BP treatment arm will be treated to a systolic BP target of &lt;140 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment strategy regarding different systolic BP goals</intervention_name>
    <description>The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (&lt;120 mmHg in the intensive arm and &lt;140 mmHg in the standard arm).</description>
    <arm_group_label>Intensive BP treatment arm</arm_group_label>
    <arm_group_label>Standard BP treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women aged ≥50 years;&#xD;
&#xD;
          2. Diabetes defined as:&#xD;
&#xD;
               -  A self-reported previous diagnosis by health care professionals and taking&#xD;
                  anti-diabetic medications;&#xD;
&#xD;
               -  Fasting plasma glucose level of ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no&#xD;
                  caloric intake for at least 8 hours;&#xD;
&#xD;
               -  2-hour plasma glucose level of ≥200 mg/dL (11.1 mmol/L) during an oral glucose&#xD;
                  tolerance test. The test should be performed using a glucose load containing the&#xD;
                  equivalent of 75 g anhydrous glucose dissolved in water; or&#xD;
&#xD;
               -  HbA1c concentration of ≥6.5% (48 mmol/mol);&#xD;
&#xD;
          3. Systolic blood pressure&#xD;
&#xD;
             -≥140 mmHg on 0 medication;&#xD;
&#xD;
               -  130-180 mmHg on 1 medication;&#xD;
&#xD;
               -  130-170 mmHg on up to 2 medications;&#xD;
&#xD;
               -  130-160 mmHg on up to 3 medications; or&#xD;
&#xD;
               -  130-150 mmHg on up to 4 medications;&#xD;
&#xD;
          4. Increased risk of cardiovascular disease (one or more of the following):&#xD;
&#xD;
               -  Previous history of clinical CVD (≥ 3 months)&#xD;
&#xD;
               -  Subclinical CVD within 3 years&#xD;
&#xD;
               -  2 or more CVD risk factors&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) 30-59 ml/min/1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History consistent with type 1 diabetes&#xD;
&#xD;
          2. Known secondary cause of hypertension&#xD;
&#xD;
          3. One minute standing systolic BP &lt;110 mmHg&#xD;
&#xD;
          4. Arm circumference too large to allow accurate blood pressure measurement with&#xD;
             available devices&#xD;
&#xD;
          5. Cardiovascular event or procedure or hospitalization for unstable angina within the&#xD;
             past 3 months&#xD;
&#xD;
          6. Symptomatic heart failure within the past 6 months or left ventricular ejection&#xD;
             fraction (by any method) &lt;35% within the past 6 months&#xD;
&#xD;
          7. ALT or AST levels more than twice the upper limit of the normal range or active liver&#xD;
             diseases&#xD;
&#xD;
          8. Dialysis, kidney transplantation, eGFR &lt;30 ml/min/1.73 m2, or serum creatinine &gt;2.0&#xD;
             mg/dl&#xD;
&#xD;
          9. Proteinuria&#xD;
&#xD;
         10. Previous diagnosis of polycystic kidney disease or glomerulonephritis&#xD;
&#xD;
         11. A medical condition likely to limit survival to less than 5 years&#xD;
&#xD;
         12. Any factors judged by the clinic team to be likely to limit adherence to interventions&#xD;
&#xD;
         13. Failure to obtain informed consent from participant&#xD;
&#xD;
         14. Currently participating in another intervention study&#xD;
&#xD;
         15. Currently living with another BPROAD participant&#xD;
&#xD;
         16. Pregnancy, currently trying to become pregnant, or of child-bearing potential and not&#xD;
             using birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guang Ning, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Xu, MD, PhD</last_name>
    <phone>+86-15921811120</phone>
    <email>jane.yuxu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yufang Bi, MD, PhD</last_name>
    <phone>+86-21-64370045</phone>
    <phone_ext>663340</phone_ext>
    <email>byf10784@rjh.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang Ning, MD, PhD</last_name>
      <phone>+86-21-64370045</phone>
      <phone_ext>665344</phone_ext>
      <email>feifei1116@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yu Xu, MD, PhD</last_name>
      <phone>+86-21-64370045</phone>
      <phone_ext>663340</phone_ext>
      <email>jane.yuxu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guang Ning, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Guang Ning</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

